AMGEN - Sharing, Shedding = Gaining!
News flow from Amgen’s (AMGN) pipeline highlights its focus to create maximum value through innovation and operational efficiency. Strategic collaboration with AZN for the inflammation portfolio of 5 mAbs (AMGN gets upfront $50m + low to mid single-digit royalty + equal profit sharing) could be a win-win for both the companies, but the terms favor AMGN more. We expect post-AZN collaboration R&D expenses update should reflect favorably on the bottom line. Favorable clinical data increases the visibility of pipeline… For more details, please read our report released on April 5th, 2012 on AMGN, titled “Sharing, Shedding = Gaining!”
COMPANIES MENTIONED
AMGEN
AMGEN
More Publications
AMGEN: Innovation + Emerging Market – A Balanced Approach!
US$ 140.00
May 2012
7 pages
Biogen Idec - BG-12: Next Oral MS Pill - Driving Valuations
US$ 140.00
July 2012
4 pages
ASTRAZENECA - First in class Forxiga (dapagliflozin) approved in Europe – Diabetes portfolio may heal AstraZeneca’s pains
US$ 90.00
November 2012
3 pages
Pfizer- Bapineuzumab IV Discontinuation cuts Speculation value in PFE price
US$ 90.00
August 2012
1 pages
Ambit Biosciences (AMBI) - Early Approval of Quizartinib in RR-AML = A Risk Worth Taking
US$ 200.00
August 2013
10 pages
